Market Overview

Regeneron Pharmaceuticals Earnings Outlook

Related REGN
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
Earnings Scheduled For November 6, 2018
Ziopharm slips 1% after hours following release of early-stage data on gene therapy Controlled IL-12 (Seeking Alpha)

Regeneron Pharmaceuticals (NASDAQ: REGN) announces its next round of earnings this Thursday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.

Earnings and Revenue

Regeneron earnings will be near $4.70 per share on sales of $1.56 billion, according to analysts.

Regeneron earnings in the same period a year ago was $4.17. Quarterly sales came in at $1.47 billion. The Wall Street estimate would represent a 12.71 percent increase in the company's earnings. Revenue would be up 6.12 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q1 2018 Q4 2017 Q3 2017 Q2 2017
EPS Estimate 4.32 4.52 3.85 3.16
EPS Actual 4.67 5.23 3.99 4.17

Stock Performance

Over the last 52-week period, shares are down 27.66 percent. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release. Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. Analysts seem to have settled on a Neutral rating with Regeneron. The strength of this rating has maintained conviction over the past three months.

Conference Call

Regeneron's Q2 conference call is scheduled to begin at 8:30 a.m. ET and can be accessed here:

Posted-In: Earnings News


Related Articles (REGN)

View Comments and Join the Discussion!

Q2 Earnings Preview For Apollo Global Management

Jogging In Place: Fed Leaves Rates Alone, Strikes Positive Tone In Post-Meeting Statement